Clinical trials: in Austria
Medulloblastoma Recurrent, Ependymoma Recurrent
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy…
- Conditions
- Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent
- Trial name
- MEMMAT (NCT01356290)
- Testing
- Bevacizumab, Thalidomide, Celecoxib
- Where
- 22 sites in United States, Austria and 6 more
- Volunteers
- 232 people
- Sponsor
- Medical University of Vienna
Breast Cancer, Early Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who…
- Trial name
- CAMBRIA-1 (NCT05774951)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 709 sites in United States, Argentina and 37 more
- Volunteers
- 4,300 people
- Sponsor
- AstraZeneca
Essential Tremor
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of…
- Trial name
- NCT04032470
- Testing
- Deep Brain Stimulation Systems (DBS)
- Where
- 20 sites in Austria, Belgium and 7 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Non-small Cell Lung Cancer (NSCLC)
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without…
- Trial name
- TROPION-Lung17 (NCT07291037)
- Testing
- Datopotamab deruxtecan (Dato-DXd), Docetaxel
- Where
- 206 sites in United States, Australia and 19 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Non-alcoholic Steatohepatitis
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.
- Trial name
- ESSENCE (NCT04822181)
- Testing
- Semaglutide
- Where
- 558 sites in United States, Argentina and 37 more
- Volunteers
- 1,205 people
- Sponsor
- Novo Nordisk A/S
Endometrial Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.
- Trial name
- TroFuse-033 (NCT06952504)
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 268 sites in United States, Argentina and 32 more
- Volunteers
- 1,123 people
- Sponsor
- Merck Sharp & Dohme LLC
Choroidal Melanoma, Indeterminate Lesions
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- CoMpass (NCT06007690)
- Testing
- Bel-sar, Suprachoroidal Microinjector, Infrared Laser
- Where
- 53 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Aura Biosciences
Vespid Venom Allergy
Is the BAT Inhibition Able to Replace Sting Challenges? (BATIRS)
Insect venom allergy is the major cause for severe allergic reactions in Europe. Wasps and honeybees are responsible for the majority of these allergic reactions.
- Trial name
- NCT04438525
- Testing
- sting challenge, blood donation
- Where
- Austria
- Volunteers
- 219 people
- Sponsor
- Medical University of Graz
Liver Cirrhosis
AGRA Before and After Liver Transplantation
The immune system is impaired in liver cirrhotic patients, which is associated with a high risk for bacterial infections and worse outcome.
- Trial name
- NCT03446521
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Medical University of Graz
Arthrosis, Traumatic Arthritis
The Medacta International SMS Post-Marketing Surveillance Study
This is a Post-Marketing Surveillance of SMS femoral stem prosthesis.
- Conditions
- Arthrosis, Traumatic Arthritis, Rheumatoid Polyarthritis, Congenital Hip Dysplasia
- Trial name
- NCT02748408
- Testing
- SMS femoral stem
- Where
- 4 sites in Austria, Italy and 2 more
- Volunteers
- 550 people
- Sponsor
- Medacta International SA
Diffuse Cutaneous Systemic Sclerosis
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo
- Trial name
- NCT06470048
- Testing
- Ianalumab
- Where
- 106 sites in United States, Argentina and 23 more
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML)
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children.
- Trial name
- NCT06679582
- Testing
- Luveltamab tazevibulin
- Where
- 36 sites in United States, Austria and 7 more
- Volunteers
- 1 people
- Sponsor
- Sutro Biopharma, Inc.
Covid19
Post COVID-19 Syndrome and the Gut-lung Axis
The outbreak of the novel coronavirus (SARS-CoV-2)-infected disease (COVID-19) began in December 2019, spread throughout China in early 2020 and developed as a pandemic thereafter.
- Trial name
- NCT04813718
- Testing
- Omni-Biotic Pro Vi 5
- Where
- Austria
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Secondary Sclerosis Cholangitis in Critically Ill Patients
Secondary Sclerosis Cholangitis Prospective
SC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. Gut microbiome composition, gut permeability, bacterial translocation, inflammation and/or genetic variants contribute to the…
- Trial name
- SSCpro (NCT03566797)
- Where
- Austria
- Volunteers
- 380 people
- Sponsor
- Medical University of Graz
Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06824467
- Testing
- Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist
- Where
- 198 sites in United States, Argentina and 27 more
- Volunteers
- 770 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored…
- Trial name
- NCT02960022
- Testing
- enzalutamide, abiraterone acetate, prednisone
- Where
- 233 sites in United States, Argentina and 36 more
- Volunteers
- 900 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Diffuse Large B-Cell Lymphoma
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects…
- Trial name
- ESCALADE (NCT04529772)
- Testing
- acalabrutinib, Prednisone, Rituximab
- Where
- 245 sites in United States, Australia and 21 more
- Volunteers
- 611 people
- Sponsor
- Acerta Pharma BV
Liver Cirrhosis
Periinterventional Coagulation Management of Patients Undergoing a TIPS
Assess whether a pre-interventional thrombelastography guided algorithm for assessing and correction of coagulation status in cirrhotic patients is safe and effective
- Trial name
- TIPSprosp (NCT04421924)
- Testing
- thrombelastogram, standard of care
- Where
- Austria
- Volunteers
- 39 people
- Sponsor
- Medical University of Graz
Multiple Myeloma, Secondary Immunodeficiency
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants…
- Trial name
- NCT06980480
- Testing
- IGI, 10%
- Where
- 65 sites in United States, Australia and 15 more
- Volunteers
- 183 people
- Sponsor
- Takeda
Secondary Sclerosing Cholangitis
Secondary Sclerosing Cholangitis in Critically Ill Patients
SSC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. The investigators hypothesize that genetic variants of biliary transporter genes are frequent in patients with SSC-CIP.
- Trial name
- SSC-CIP (NCT02545309)
- Where
- Austria
- Volunteers
- 140 people
- Sponsor
- Medical University of Graz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.